<DOC>
	<DOCNO>NCT01043640</DOCNO>
	<brief_summary>Rationale : Chemotherapy administration donor stem cell transplant necessary stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , donor white blood cell provide miss enzyme cause metabolic disease . Sometimes transplanted cell donor make immune response body 's normal cell . Giving monoclonal antibody , alemtuzumab , transplant cyclosporine mycophenolate mofetil transplant may stop happen . This may effective treatment inherit metabolic disorder . Purpose : The design study achieve donor cell engraftment patient standard-risk inherited metabolic disease limit peri-transplant morbidity mortality . This achieved administration chemotherapy regimen describe . The intention follow transplant patient year transplant monitoring complication disease assist family multifaceted interdisciplinary approach .</brief_summary>
	<brief_title>Allogeneic Bone Marrow Transplant Inherited Metabolic Disorders</brief_title>
	<detailed_description>Primary Objective : - To estimate proportion patient donor derived engraftment day 100 post transplant define 80 % great donor cell CD3 ( T cell ) fraction Secondary Objectives : - To determine incidence severity graft-versus-host disease ( GVHD ) day 100 - To determine incidence peri-transplant mortality ( death day 100 ) - To monitor donor cell chimerism various time point follow allogeneic transplantation transplant regimen determine day 28 , 42 , 100 , 6 month yearly 5 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<mesh_term>Sphingolipidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<mesh_term>Mucopolysaccharidosis VII</mesh_term>
	<mesh_term>Fucosidosis</mesh_term>
	<mesh_term>Peroxisomal Disorders</mesh_term>
	<mesh_term>Aspartylglucosaminuria</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Must diagnosis one following : mucopolysaccharidosis disorder , glycoprotein metabolic disorder , sphingolipidoses inherited leukodystrophy , peroxisomal disorder inherit disease metabolism Must acceptable graft source define University Minnesota criterion Adequate organ function Pregnant menstruate female must negative serum pregnancy test within 14 day treatment start Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>inherit metabolic disorder</keyword>
</DOC>